rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

IGC Pharma, Inc.

IGC · NYSE American

Health CareBiotechnologyNot moving yet

IGC stood above a rising 150-day average in 6 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 12.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
36 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders36+2 on the quarter
New · exited8 · 5
Reported value$1.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026879,394$239K-163,990−15.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026814,914$222K+96,478+13.4%
BlackRock, Inc.unchanged · filed 7 Aug 2026703,798$191K00.0%
AdvisorShares Investments LLCnew · filed 11 Aug 2026678,480$185K+678,480
CITADEL ADVISORS LLCnew · filed 14 Aug 2026437,317$119K+437,317
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026419,413$114K+3,525+0.8%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026286,608$78K-197,367−40.8%
STATE STREET CORPunchanged · filed 7 Aug 2026200,799$55K00.0%
NORTHERN TRUST CORPadded · filed 13 Aug 2026170,274$46K+56,867+50.1%
LAWOOD & COunchanged · filed 13 Jul 202675,000$20K00.0%
31 Mar 2023 – 30 Jun 2026
192735Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Claudia Grimaldi Company insiderPFO · last 25 Sep 20260 · 2
Ram Mukunda Company insiderCEO · last 25 Sep 20261 · 13
James P. Moran Company insiderDirector · last 1 Apr 20261 · 0
Richard K. Prins Company insiderDirector · last 1 Apr 20261 · 5
Terry L. Lierman Company insiderDirector · last 17 Oct 20250 · 0
Bradbury Strategic Investment Fund A (Cayman Islands Registration No. Cr-359857) Company insider10% owner · last 22 Mar 20240 · 0
John Edward Lynch Company insiderDirector · last 1 Jun 20220 · 0
Rohit Goel Company insiderSenior Director of Finance&PAO · last 13 May 20210 · 0
Sudhakar V. Shenoy Company insiderDirector · last 11 Jun 20191 · 0
John Cherin Company insiderCFO, Treasurer and PAO · last 13 Sep 20170 · 0
Shu Kwong Ngai Company insiderInterim CFO · last 19 Apr 20131 · 0
Ranga C. Krishna Company insiderDirector · last 7 Aug 201214 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Mar 202548.7%
Operating profit marginFY 2025 · to 31 Mar 2025-586%
Free cash flow marginFY 2025 · to 31 Mar 2025-386%
Return on capital employedFY 2025 · to 31 Mar 2025-115%
Debt to equityFY 2025 · to 31 Mar 20250.02×
Research spendFY 2025 · to 31 Mar 2025288%
Share count trendFY 2025 · to 20 Jun 20253.7%
Cash and equivalentsFY 2025 · to 31 Mar 2025$405K
Free cash flowFY 2025 · to 31 Mar 2025−$4.9M

Analyst forecasts

No analyst forecasts yet.